Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate.
Read More…
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorFinance
CIKN/A
Phone212-590-9070
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$12.12 million
Profitability
Miscellaneous
Employees291
Next Earnings Date11/12/2019 (Confirmed)
OptionableOptionable
Cronos Group (NASDAQ:CRON) Frequently Asked Questions
What is Cronos Group's stock symbol?
Cronos Group trades on the NASDAQ under the ticker symbol "CRON."
How were Cronos Group's earnings last quarter?
Cronos Group Inc (NASDAQ:CRON) released its earnings results on Thursday, August, 8th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.01. The firm earned $10.80 million during the quarter, compared to analysts' expectations of $7.16 million. Cronos Group had a return on equity of 60.20% and a net margin of 2,521.25%. Cronos Group's revenue was up 217.6% compared to the same quarter last year. View Cronos Group's Earnings History.
When is Cronos Group's next earnings date?
How can I listen to Cronos Group's earnings call?
Cronos Group will be holding an earnings conference call on Tuesday, November 12th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for CRON?
13 brokerages have issued 12 month price targets for Cronos Group's stock. Their forecasts range from $14.00 to $30.00. On average, they anticipate Cronos Group's share price to reach $20.55 in the next twelve months. This suggests a possible upside of 147.0% from the stock's current price. View Analyst Price Targets for Cronos Group.
What is the consensus analysts' recommendation for Cronos Group?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last year. There are currently 1 sell rating, 8 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cronos Group.
Has Cronos Group been receiving favorable news coverage?
News stories about CRON stock have trended somewhat positive on Sunday, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Cronos Group earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Cronos Group.
Who are some of Cronos Group's key competitors?
Some companies that are related to Cronos Group include Canopy Growth (CGC), STADA Arzneimittel (STDAF), Aurora Cannabis (ACB), Tilray (TLRY), USANA Health Sciences (USNA), Canopy Rivers (RIV), Sundial Growers (SNDL), Chromadex (CDXC), Foamix Pharmaceuticals (FOMX), True Drinks (TRUU), Mediwound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN) and FitLife Brands (FTLF).
What other stocks do shareholders of Cronos Group own?
Who are Cronos Group's key executives?
Cronos Group's management team includes the folowing people:
- Mr. Michael Gorenstein, Chairman, Pres & CEO (Age 31)
- Mr. David Hsu, Chief Operating Officer
- Ms. Xiuming Shum, Gen. Counsel & Corp. Sec.
- Mr. Jeffrey Jacobson, Head of Sales & Bus. Devel.
- Mr. William Hilson, Chief Commercial Officer
Who are Cronos Group's major shareholders?
Cronos Group's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.02%), Exane Derivatives (0.01%), SeaCrest Wealth Management LLC (0.01%), Valeo Financial Advisors LLC (0.00%) and Wealthcare Advisory Partners LLC (0.00%).
Which institutional investors are selling Cronos Group stock?
CRON stock was sold by a variety of institutional investors in the last quarter, including Exane Derivatives and SeaCrest Wealth Management LLC.
Which institutional investors are buying Cronos Group stock?
CRON stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., Valeo Financial Advisors LLC and Wealthcare Advisory Partners LLC.
How do I buy shares of Cronos Group?
Shares of CRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cronos Group's stock price today?
One share of CRON stock can currently be purchased for approximately $8.32.
How big of a company is Cronos Group?
Cronos Group has a market capitalization of $2.84 billion and generates $12.12 million in revenue each year. The company earns $-14,640,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis. Cronos Group employs 291 workers across the globe.View Additional Information About Cronos Group.
What is Cronos Group's official website?
How can I contact Cronos Group?
Cronos Group's mailing address is 720 KING STREET W SUITE 320, TORONTO A6, M5V 2T3. The company can be reached via phone at 212-590-9070.
MarketBeat Community Rating for Cronos Group (NASDAQ CRON)
MarketBeat's community ratings are surveys of what our community members think about Cronos Group and other stocks. Vote "Outperform" if you believe CRON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRON will underperform the S&P 500 over the long term. You may vote once every thirty days.
